IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas | MicrobiomeTrials← Back to trialsNCT05365659
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2023-09-05Est. Completion: 2027-09
Enrollment target: 140 participants Locations- University of Maryland Baltimore, Baltimore, Maryland, United States
- Westmead Hospital, Westmead, New South Wales, Australia
- Royal Adelaide Hospital, Adelaide, South Australia, Australia
- Royal Hobart Hospital, Hobart, Tasmania, Australia
- Linear Clinical Research, Perth, Western Australia, Australia
- Jewish General Hospital, Montreal, Quebec, Canada
- Istituto Nazionale Oncologico Candiolo, Candiolo, Italy
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy
- Istituto Europeo Clinico Humanitas, Milan, Italy
- Istituto Europeo di Oncologia, Milan, Italy
- Institut Catala D'Oncologia, Badalona, Spain
- Hospital Universitario Quironsalud Madrid, Madrid, Spain
- Hospital Clinico Universitario de Salamanca, Salamanca, Spain
Other microbiome trials you might be interested in
Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
This phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab a…
Los Angeles, United StatesEst. completion Apr 1, 2027
Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to …
Birmingham, United StatesEst. completion Jun 23, 2023